Crimean-Congo Hemorrhagic Fever (CCHF) is a tick-borne virus. It was first identified in Crimea in 1944 and was later detected in Congo in 1969. It is endemic where it is mainly located in regions such as Africa, Europe, and Asia. CCHF is primarily transmitted through the bite of an infected tick, however direct contact with bodily fluids can also be another route of transmission. Specifically, Hyalomma ticks are the main reservoirs and vectors of CCHF. Symptoms may range from asymptomatic to severe development of hemorrhage, with a fatality rate of up to 40%. Initial symptoms include headaches, high fevers, body pain, vomiting, etc. More severe symptoms can include severe bruising and bleeding, or hemorrhage. Diagnosis of CCHF can be done with an ELISA test, along with other laboratory tests. Currently, there is no successful vaccine that exists for CCHF, however research has been conducted in efforts to create a RNA vaccine that combats the virus. To treat this virus, Ribavirin is likely the antiviral drug choice as it functions as a virus inhibitor. Currently, there have been no cases reported in the United States, however, climate changes can influence the migration of ticks to certain habitats and impact the risk of exposure.